Chorea

CONTINUUM Lifelong Learning in Neurology

Volumn 19, Issue 5, 2013, Pages 1242-1263

  Walker, Ruth H ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYL COENZYME A ACYLTRANSFERASE; ADENINE; ALPHA FETOPROTEIN; AMINO ACID; ANTIDEPRESSANT AGENT; ANTIGEN; ANTISTREPTOLYSIN; BENZODIAZEPINE DERIVATIVE; CALCIUM; CERULOPLASMIN; CHOLESTEROL; CHOLINERGIC RECEPTOR BLOCKING AGENT; CREATINE KINASE; DEOXYRIBONUCLEASE; DOPAMINE; ELECTROLYTE; FERRITIN; GLIADIN ANTIBODY; LACTIC ACID; LIVER ENZYME; LUPUS ANTICOAGULANT; MITOCHONDRIAL DNA; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NUCLEOTIDE; PARATHYROID HORMONE; PHOSPHOLIPID ANTIBODY; PYRUVATE DEHYDROGENASE; TETRABENAZINE; UNINDEXED DRUG; URIC ACID;

ACANTHOCYTOSIS; ATAXIA; ATAXIA TELANGIECTASIA; AUTOSOMAL DOMINANT INHERITANCE; AUTOSOMAL RECESSIVE INHERITANCE; BASAL GANGLION; BLOOD CELL COUNT; BONE MARROW BIOPSY; BRAIN DEPTH STIMULATION; CAG REPEAT; CEREBRAL PALSY; CEREBROVASCULAR ACCIDENT; CHOREA; CHOREA-ACANTHOCYTOSIS; CLINICAL FEATURE; COGNITIVE DEFECT; CONGENITAL HYPOTHYROIDISM; DENTATORUBROPALLIDOLUYSIAN ATROPHY; DISEASE COURSE; DISEASES; DYSTONIA; ERYTHROCYTE; FAMILY HISTORY; FRIEDREICH ATAXIA; GENE; GENETIC COUNSELING; GENETIC SCREENING; GENETICS; GLUCOSE BLOOD LEVEL; HEREDITARY METHEMOGLOBINEMIA; HUMAN; HUNTINGTON CHOREA; HYPERGLYCINEMIA; HYPERTRANSAMINASEMIA; LABORATORY; LABORATORY TEST; LEIGH DISEASE; LESCH NYHAN SYNDROME; LUMBAR PUNCTURE; MCLEOD SYNDROME; MENTAL DISEASE; METABOLIC DISORDER; MOLECULAR THERAPY; NEUROIMAGING; NEUROLOGIC DISEASE; NEUROLOGIC EXAMINATION; NUCLEAR MAGNETIC RESONANCE IMAGING; ONSET AGE; PARANEOPLASTIC SYNDROME; PARKINSONISM; PHENOTYPE; REVIEW; TENDON REFLEX; TRINUCLEOTIDE REPEAT; WILSON DISEASE;

ADULT; AGED; CHOREA; DISEASE PROGRESSION; FEMALE; HUMANS; LIVER DISEASES; MALE; MEDICAL HISTORY TAKING; MENTAL DISORDERS; MIDDLE AGED; MITOCHONDRIAL DISEASES; MUTATION; NEUROIMAGING; NEUROLOGIC EXAMINATION; PEDIGREE; PERIPHERAL NERVOUS SYSTEM DISEASES;

EID: 84885625658     PISSN: 10802371     EISSN: 15386899     Source Type: Journal    
DOI: 10.1212/01.CON.0000436155.46909.c3     Document Type: Review

References (62)

1. Albanese A, Bhatia K, Bressman S, et al. Phenomenology and classification of dystonia: a consensus update [published online ahead of print May 6, 2013]. Mov Disord doi: 10.1002/mds.25475.
2. Klein C. Movement disorders: classifications. J Inherit Metab Dis 2005;28(3):425-439. (Pubitemid 40723876)
3. Fuchs T, Ozelius LJ. Genetics of dystonia. Semin Neurol 2011;31(5):441-448.
4. Thompson VB, Jinnah HA, Hess EJ. Convergent mechanisms in etiologically-diverse dystonias. Expert Opin Ther Targets 2011;15(12): 1387-1403.
5. Marras C, Lohmann K, Lang A, et al. Fixing the broken system of genetic locus symbols: Parkinson disease and dystonia as examples. Neurology 2012;78(13): 1016-1024.
6. Xiao J, Uitti RJ, Zhao Y, et al. Mutations in CIZ1 cause adult onset primary cervical dystonia. Ann Neurol 2012;71(4):458-469.
7. Charlesworth G, Plagnol V, Holmstrom KM, et al. Mutations in ANO3 cause dominant craniocervical dystonia: ion channel implicated in pathogenesis. Am J Hum Genet 2012;91(6): 1041-1050.
8. Fuchs T, Saunders-Pullman R, Masuho I, et al. Mutations in GNAL cause primary torsion dystonia. Nat Genet 2012;45(1):88-92.
9. Lohmann K, Wilcox RA, Winkler S, et al. Whispering dysphonia (DYT4 dystonia) is caused by a mutation in the TUBB4 gene [published online ahead of print December 13, 2012]. Ann Neurol doi: 10.1002/ana.23829.
10. Hersheson J, Mencacci NE, Davis M, et al. Mutations in the autoregulatory domain of $-tubulin 4a cause hereditary dystonia [published online ahead of print December 13, 2012]. Ann Neurol. doi:10.1002/ana.23832.
11. Kabakci K, Hedrich K, Leung JC, et al. Mutations in DYT1: extension of the phenotypic and mutational spectrum. Neurology 2004;62(3):395-400. (Pubitemid 38200849)
12. Lee HY, Huang Y, Bruneau N, et al. Mutations in the gene PRRT2 cause paroxysmal kinesigenic dyskinesia with infantile convulsions. Cell Rep 2012;1(1):2-12.
13. Schmidt A, Kumar KR, Redyk K, et al. Two faces of the same coin: benign familial infantile seizures and paroxysmal kinesigenic dyskinesia caused by PRRT2 mutations. Arch Neurol 2012;69(5):668-670.
14. Ozelius LJ. Clinical spectrum of disease associated with ATP1A3 mutations. Lancet Neurol 2012;11(9):741-743.
15. Rosewich H, Thiele H, Ohlenbusch A, et al. Heterozygous de-novo mutations in ATP1A3 in patients with alternating hemiplegia of childhood: a whole-exome sequencing gene-identification study. Lancet Neurol 2012;11(9):764-773.
16. Hagenah J, Reetz K, Zuhlke C, et al. Predominant dystonia with marked cerebellar atrophy: a rare phenotype in familial dystonia. Neurology 2007;68(24):2157; author reply 2157-2158. (Pubitemid 46912143)
17. Ozelius LJ, Hewett JW, Page CE, et al. The early-onset torsion dystonia gene (DYT1) encodes an ATP-binding protein. Nat Genet 1997;17(1):40-48. (Pubitemid 27377530)
18. Fuchs T, Gavarini S, Saunders-Pullman R, et al. Mutations in the THAP1 gene are responsible for DYT6 primary torsion dystonia. Nat Genet 2009;41(3):286-288.
19. Seibler P, Djarmati A, Langpap B, et al. A heterozygous frameshift mutation in PRKRA (DYT16) associated with generalised dystonia in a German patient. Lancet Neurol 2008;7(5):380-381. (Pubitemid 351508475)
20. Waddy HM, Fletcher NA, Harding AE, Marsden CD. A genetic study of idiopathic focal dystonias. Ann Neurol 1991;29(3): 320-324.
21. Groen JL, Kallen MC, van de Warrenburg BP, et al. Phenotypes and genetic architecture of focal primary torsion dystonia. J Neurol Neurosurg Psychiatry 2012;83(10): 1006-1011.
22. Tadic V, Kasten M, Bruggemann N, et al. Dopa-responsive dystonia revisited: diagnostic delay, residual signs, and nonmotor signs. Arch Neurol 2012;1-5.
23. Bruggemann N, Spiegler J, Hellenbroich Y, et al. Beneficial prenatal levodopa therapy in autosomal recessive guanosine triphosphate cyclohydrolase 1 deficiency. Arch Neurol 2012; 69(8):1071-1075.
24. Grunewald A, Djarmati A, Lohmann-Hedrich K, et al. Myoclonus-dystonia: significance of large SGCE deletions. Hum Mutat 2008;29(2): 331-332.
25. Martella G, Tassone A, Sciamanna G, et al. Impairment of bidirectional synaptic plasticity in the striatum of a mouse model of DYT1 dystonia: role of endogenous acetylcholine. Brain 2009;132(pt 9):2336-2349.
26. Neychev VK, Gross RE, Lehericy S, et al. The functional neuroanatomy of dystonia. Neurobiol Dis 2011;42(2):185-201.
27. Volkmann J, Wolters A, Kupsch A, et al. Pallidal deep brain stimulation in patients with primary generalised or segmental dystonia: 5-year follow-up of a randomised trial. Lancet Neurol 2012;11(12):1029-1038.
28. Carbon M, Argyelan M, Habeck C, et al. Increased sensorimotor network activity in DYT1 dystonia: a functional imaging study. Brain 2010;133(pt 3):690-700.
29. Etgen T, Muhlau M, Gaser C, Sander D. Bilateral grey-matter increase in the putamen in primary blepharospasm. J Neurol Neurosurg Psychiatry 2006;77(9): 1017-1020. (Pubitemid 44338520)
30. Egger K, Mueller J, Schocke M, et al. Voxel based morphometry reveals specific gray matter changes in primary dystonia. Mov Disord 2007;22(11):1538-1542. (Pubitemid 47477912)
31. Bradley D, Whelan R, Walsh R, et al. Temporal discrimination threshold: VBM evidence for an endophenotype in adult onset primary torsion dystonia. Brain 2009;132(pt 9):2327-2335.
32. Quartarone A, Rizzo V, Morgante F. Clinical features of dystonia: a pathophysiological revisitation. Curr Opin Neurol 2008;21(4): 484-490.
33. Berardelli A, Abbruzzese G, Chen R, et al. Consensus paper on short-interval intracortical inhibition and other transcranial magnetic stimulation intracortical paradigms in movement disorders. Brain Stimul 2008;1(3):183-191.
34. Sohn YH, Hallett M. Disturbed surround inhibition in focal hand dystonia. Ann Neurol 2004;56(4):595-599. (Pubitemid 39319356)
35. Houdayer E, Beck S, Karabanov A, et al. The differential modulation of the ventral premotor-motor interaction during movement initiation is deficient in patients with focal hand dystonia. Eur J Neurosci 2012;35(3):478-485.
36. Nistico R, Pirritano D, Salsone M, et al. Blink reflex recovery cycle in patients with dystonic tremor: a cross-sectional study. Neurology 2012;78(17):1363-1365.
37. Fiorio M, Gambarin M, Valente EM, et al. Defective temporal processing of sensory stimuli in DYT1 mutation carriers: a new endophenotype of dystonia? Brain 2007;130(pt 1):134-142. (Pubitemid 46026229)
38. Morgante F, Tinazzi M, Squintani G, et al. Abnormal tactile temporal discrimination in psychogenic dystonia. Neurology 2011;77(12): 1191-1197.
39. Quartarone A, Rizzo V, Terranova C, et al. Abnormal sensorimotor plasticity in organic but not in psychogenic dystonia. Brain 2009;132(pt 10):2871-2877.
40. Morgante F, Espay AJ, Gunraj C, et al. Motor cortex plasticity in Parkinson's disease and levodopa-induced dyskinesias. Brain 2006;129(pt 4):1059-1069.
41. Ruge D, Tisch S, Hariz MI, et al. Deep brain stimulation effects in dystonia: time course of electrophysiological changes in early treatment. Mov Disord 2011;26(10): 1913-1921.
42. Argyelan M, Carbon M, Niethammer M, et al. Cerebellothalamocortical connectivity regulates penetrance in dystonia. J Neurosci 2009;29(31):9740-9747.
43. Avanzino L, Abbruzzese G. How does the cerebellum contribute to the pathophysiology of dystonia? Basal Ganglia 2012;2(4):231-235.
44. Delnooz CC, Horstink MW, Tijssen MA, et al. Paramedical treatment in primary dystonia: a systematic review. Mov Disord 2009; 24(15):2187-2198.
45. Albanese A. Terminology for preparations of botulinum neurotoxins: what a difference a name makes. JAMA 2011;305(1):89-90.
46. Albanese A, Asmus F, Bhatia KP, et al. EFNS guidelines on diagnosis and treatment of primary dystonias. Eur J Neurol 2011;18(1): 5-18.
47. Simpson DM, Blitzer A, Brashear A, et al. Assessment: Botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2008;70(19): 1699-1706. (Pubitemid 351644138)
48. Hallett M, Albanese A, Dressler D, et al. Evidence-based review and assessment of botulinum neurotoxin for the treatment of movement disorders [published online ahead of print February 4, 2013]. Toxicon. doi:10.1016/j.toxicon.2012.12.004.
49. Bentivoglio AR, Fasano A, Ialongo T, et al. Fifteen-year experience in treating blepharospasm with Botox or Dysport: same toxin, two drugs. Neurotox Res 2009;15(3):224-231.
50. Colosimo C, Tiple D, Berardelli A. Efficacy and safety of long-term botulinum toxin treatment in craniocervical dystonia: a systematic review. Neurotox Res 2012;22(4): 265-273.
51. Djebbari R, du Montcel ST, Sangla S, et al. Factors predicting improvement in motor disability in writer's cramp treated with botulinum toxin. J Neurol Neurosurg Psychiatry 2004;75(12):1688-1691. (Pubitemid 39611466)
52. Hong JS, Sathe GG, Niyonkuru C, et al. Elimination of dysphagia using ultrasound guidance for botulinum toxin injections in cervical dystonia. Muscle Nerve 2012;46(4): 535-539.
53. Naumann M, Boo LM, Ackerman AH, Gallagher CJ. Immunogenicity of botulinum toxins. J Neural Transm 2013;120(2): 275-290.
54. Jankovic J. Treatment of dystonia. Lancet Neurol 2006;5(10):864-872. (Pubitemid 44715821)
55. Kenney C, Hunter C, Jankovic J. Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders. Mov Disord 2007;22(2): 193-197. (Pubitemid 46374760)
56. Damier P, Thobois S, Witjas T, et al. Bilateral deep brain stimulation of the globus pallidus to treat tardive dyskinesia. Arch Gen Psychiatry 2007;64(2):170-176. (Pubitemid 46220774)
57. Tierney TS, Lozano AM. Surgical treatment for secondary dystonia. Mov Disord 2012; 27(13):1598-1605.
58. Kupsch A, Benecke R, Muller J, et al. Pallidal deep-brain stimulation in primary generalized or segmental dystonia. N Engl J Med 2006;355(19):1978-1990. (Pubitemid 44708017)
59. Walsh RA, Sidiropoulos C, Lozano AM, et al. Bilateral pallidal stimulation in cervical dystonia: blinded evidence of benefit beyond 5 years. Brain 2013;36(pt 3): 761-769.
60. Isaias IU, Alterman RL, Tagliati M. Outcome predictors of pallidal stimulation in patients with primary dystonia: the role of disease duration. Brain 2008;131(pt 7): 1895-1902. (Pubitemid 351957466)
61. Antonini A, Morgante F. Repetitive transcranial magnetic stimulation in the treatment of dystonia. In: Stacy M, editor. Handbook of dystonia. 2nd ed. London, UK: Informa Healthcare; 2012:501-511.
62. Kranz G, Shamim EA, Lin PT, et al. Transcranial magnetic brain stimulation modulates blepharospasm: a randomized controlled study. Neurology 2010;75(16): 1465-1471.